Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Tuberculosis

Free Subscription Articles published in J Infect Dis Retrieve available abstracts of 101 articles: HTML format

Single Articles

October 2025
1. COLLINS JM, Tukvadze N, Kempker RR
   Targeting Tryptophan Metabolism for Tuberculosis Biomarkers and Host Directed Therapy.
   J Infect Dis. 2025 Oct 1:jiaf510. doi: 10.1093.
   PubMed     Abstract available
   
   
   September 2025
2. OKOYE M, Okoi C, Espy N, Mba N, et al
   Leveraging PEPFAR- and Global Fund-Supported Laboratory Network for Integrated Disease Testing: Lessons From Integrated HIV, Tuberculosis, and COVID-19 Testing in Nigeria.
   J Infect Dis. 2025;232.
   PubMed     Abstract available
   
   
   
3. SATISH BA, Sundar S, Rajmani RS, Balaji KN, et al
   Activin A mediated KAT8 expression induces ferroptosis during Mycobacterium tuberculosis infection.
   J Infect Dis. 2025 Sep 22:jiaf482. doi: 10.1093.
   PubMed     Abstract available
   
   
   
4. PAN C, Xu H, Huang M, He J, et al
   Mycobacterium tuberculosis PE_PGRS62 protein inhibits type I IFN responses to promote HIV-2 replication by directly interacting with IRF3.
   J Infect Dis. 2025 Sep 17:jiaf484. doi: 10.1093.
   PubMed     Abstract available
   
   
   
5. RAO PS, Prakash Babu S, Ezhumalai K, Knudsen S, et al
   Rifampin Exposure in Pregnant and Non-Pregnant Women with Tuberculosis in India.
   J Infect Dis. 2025 Sep 10:jiaf467. doi: 10.1093.
   PubMed     Abstract available
   
   
   August 2025
6. SARTI E, Dolle C, Wolfensberger R, Kusejko K, et al
   c-Myc inhibits macrophage antimycobacterial response in Mycobacterium tuberculosis infection.
   J Infect Dis. 2025 Aug 30:jiaf456. doi: 10.1093.
   PubMed     Abstract available
   
   
   
7. BUI VL, Ragonnet R, Hughes AE, Shipman DS, et al
   Impact of Case Detection and Covid-19-Related Disruptions on Tuberculosis In Vietnam: A Modelling Analysis.
   J Infect Dis. 2025 Aug 7:jiaf406. doi: 10.1093.
   PubMed     Abstract available
   
   
   
8. SOLANS BP, Miyakawa R, Shin M, Hesseling AC, et al
   Deriving Dosages for Levofloxacin Tuberculosis Preventive Treatment for Young People Exposed to Rifampicin-Resistant Tuberculosis.
   J Infect Dis. 2025 Aug 6:jiaf401. doi: 10.1093.
   PubMed     Abstract available
   
   
   
9. DONOHUE S, Leisching G, Keane J
   The emerging role of immunothrombosis in the control and pathogenesis of Mycobacterium tuberculosis.
   J Infect Dis. 2025 Aug 5:jiaf415. doi: 10.1093.
   PubMed     Abstract available
   
   
   July 2025
10. BOUCAU J, Ruelas Castillo J, Naidoo T, Liu Y, et al
    Inflammatory macrophages associate with tissue injury and fibrosis in a mouse model of tuberculosis.
    J Infect Dis. 2025 Jul 8:jiaf361. doi: 10.1093.
    PubMed     Abstract available
    
    
    
11. PEARSON RA, Krish KN, Whatney WE, Jaoko W, et al
    Single-cell transcriptomics reveals depletion and dysregulation of Mycobacterium tuberculosis-specific Th1 and Th17 cells early after acquisition of HIV.
    J Infect Dis. 2025 Jul 3:jiaf354. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2025
12. KRAEF C, Omland LH, Porskrog A, Larsen CS, et al
    Risk of cancer after tuberculosis disease among people with HIV in Denmark: a nationwide population-based cohort study.
    J Infect Dis. 2025 Jun 26:jiaf341. doi: 10.1093.
    PubMed     Abstract available
    
    
    
13. RYCKMAN TS, Hopkins L, Tang L, Biche P, et al
    Molecular epidemiology of Mycobacterium tuberculosis across three distinct geographic sites in South Africa.
    J Infect Dis. 2025 Jun 17:jiaf326. doi: 10.1093.
    PubMed     Abstract available
    
    
    
14. HARIKUMAR PARVATHY G, Hertz D, Bhandiwad D, Eggers L, et al
    Sex Differences in Vaccine-Induced Immunity and Protection Against Mycobacterium tuberculosis.
    J Infect Dis. 2025 Jun 17:jiaf277. doi: 10.1093.
    PubMed     Abstract available
    
    
    
15. NTSHIQA T, Nagudi J, Hamada Y, Copas A, et al
    Risk factors associated with TB infection among household contacts of microbiologically confirmed pulmonary TB patients in three high TB burden countries.
    J Infect Dis. 2025 Jun 17:jiaf320. doi: 10.1093.
    PubMed     Abstract available
    
    
    
16. LEE BY, Clemens DL, Maslesa-Galic S, Nava S, et al
    Adding Intranasal to Oral Administration of an Ultra-rapid Near Universal Drug Regimen Accelerates Relapse-free Cure of Tuberculosis in Mice.
    J Infect Dis. 2025 Jun 11:jiaf315. doi: 10.1093.
    PubMed     Abstract available
    
    
    
17. BUSTION AE, Ernest JP, Kaya F, Silva C, et al
    The kinetics of bedaquiline diffusion in tuberculous cavities open a window for emergence of resistance.
    J Infect Dis. 2025 Jun 4:jiaf303. doi: 10.1093.
    PubMed     Abstract available
    
    
    
18. KLEYNHANS L, Maasdorp E, Snyders CI, Seddon JA, et al
    Impact of puberty on immune responses to Mycobacterium tuberculosis in South African adolescents.
    J Infect Dis. 2025 Jun 2:jiaf293. doi: 10.1093.
    PubMed     Abstract available
    
    
    
19. NGARA B, Flori L, van Wijk RC, Ernest JP, et al
    Translational Modeling of BTZ-043 to Predict Phase 2A Efficacy and Evaluate Drug-Drug Interactions With Bedaquiline, Pretomanid, and Linezolid in Murine Models.
    J Infect Dis. 2025;231:e901-e911.
    PubMed     Abstract available
    
    
    May 2025
20. VEEKEN LD, Schwalb A, Horton KC, Koesoemadinata RC, et al
    Mind the clinic-community gap: how concerned should we be about false positive test results in mass tuberculosis screening?
    J Infect Dis. 2025 May 23:jiaf268. doi: 10.1093.
    PubMed     Abstract available
    
    
    
21. COLLINS JM, Bobosha K, Narayanan N, Gandhi NR, et al
    A plasma metabolic signature to diagnose pulmonary tuberculosis and monitor treatment response.
    J Infect Dis. 2025 May 8:jiaf240. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2025
22. ABDELGAWAD N, Wasserman S, Gausi K, Davis A, et al
    Population Pharmacokinetics of Rifampicin in Plasma and Cerebrospinal Fluid in Adults With Tuberculosis Meningitis.
    J Infect Dis. 2025 Apr 29:jiaf178. doi: 10.1093.
    PubMed     Abstract available
    
    
    
23. FERNANDEZ MC, Peterson GJ, Le C, Skerrett SJ, et al
    Interferon Gamma Stimulation Fails to Restrict Mycobacterium tuberculosis Growth in Human Monocyte-derived and Alveolar Macrophages.
    J Infect Dis. 2025 Apr 26:jiaf220. doi: 10.1093.
    PubMed     Abstract available
    
    
    
24. MACKAY EA, Platt G, Peloquin CA, Brooks MB, et al
    Impact of pharmacogenetics on pharmacokinetics of first-line anti-tuberculosis drugs in the HIRIF trial.
    J Infect Dis. 2025 Apr 17:jiaf195. doi: 10.1093.
    PubMed     Abstract available
    
    
    
25. LOURENS R, Singh G, Arendse T, Thwaites G, et al
    Tuberculous meningitis across the lifespan.
    J Infect Dis. 2025 Apr 8:jiaf181. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2025
26. PALADINO ME, Riva MA
    Comment On: Respiratory Isolation for Tuberculosis: A Historical Perspective.
    J Infect Dis. 2025 Mar 26:jiaf161. doi: 10.1093.
    PubMed    
    
    
    
27. THEODOROU DJ, Theodorou SJ
    Respiratory isolation of patients with tuberculosis: Is the way forward paved?
    J Infect Dis. 2025 Mar 17:jiaf143. doi: 10.1093.
    PubMed    
    
    
    
28. FOLKESSON E, Froberg G, Sundling C, Schon T, et al
    Improved detection of extrapulmonary and paucibacillary pulmonary tuberculosis by Xpert MTB Host Response in a TB low endemic, high resource setting.
    J Infect Dis. 2025 Mar 6:jiaf110. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2025
29. FU Y, Yang X, Ling Q, Huang Y, et al
    USP25 Promotes the Antimycobacterial Response of Macrophages Through Stabilizing B-Raf and C-Raf.
    J Infect Dis. 2025;231:366-377.
    PubMed     Abstract available
    
    
    
30. NAN Y, Wang Y, Dong Y, Liu Y, et al
    Impact of Hypoxia-Inducible Factor-1alpha on Host Immune Metabolism and Tissue Damage During Mycobacterium bovis Infection.
    J Infect Dis. 2025;231:355-365.
    PubMed     Abstract available
    
    
    
31. 
    Correction to: Predictive Markers of Incident Tuberculosis in Close Contacts in Brazil and India.
    J Infect Dis. 2025 Feb 17:jiaf078. doi: 10.1093.
    PubMed    
    
    
    
32. CHOW FC, Kafeero P, Muhumuza P, Nakimbugwe M, et al
    Safety and Tolerability of a Short Course of Linezolid for the Treatment of Predominantly Moderate to Severe Tuberculous Meningitis in Adults with HIV.
    J Infect Dis. 2025 Feb 17:jiaf089. doi: 10.1093.
    PubMed     Abstract available
    
    
    
33. DEKKERS BGJ, Kerstjens HAM, Breisnes HW, Leeming DJ, et al
    Azithromycin as host-directed therapy for pulmonary tuberculosis - a randomized pilot trial.
    J Infect Dis. 2025 Feb 11:jiaf069. doi: 10.1093.
    PubMed     Abstract available
    
    
    
34. HUGHES JA, Solans BP, Garcia-Prats AJ, Draper HR, et al
    Pharmacokinetics and safety of clofazimine in children with rifampicin-resistant tuberculosis.
    J Infect Dis. 2025 Feb 11:jiaf057. doi: 10.1093.
    PubMed     Abstract available
    
    
    
35. KOLLMANN TR, Amenyogbe N, Schaltz-Buchholzer F, Baek O, et al
    Is systemic dissemination of BCG following neonatal vaccination required for protection against M. tuberculosis?
    J Infect Dis. 2025 Feb 6:jiaf051. doi: 10.1093.
    PubMed     Abstract available
    
    
    
36. KATES OS, Shah M
    Integrating Ethics in Public Health Guideline Development: Case Study of Guidelines on Respiratory Isolation for Persons With Tuberculosis in Community Settings.
    J Infect Dis. 2025;231:23-30.
    PubMed     Abstract available
    
    
    
37. BONOMO EJ, Shah M
    Rights-Based Legal Considerations for Tuberculosis Isolation Practices in Community Settings in the Postpandemic Era.
    J Infect Dis. 2025;231:31-36.
    PubMed     Abstract available
    
    
    January 2025
38. STOLTZ A, Nathavitharana RR, de Kock E, Ueckermann V, et al
    Estimating the Early Transmission Inhibition of new treatment regimens for drug-resistant tuberculosis.
    J Infect Dis. 2025 Jan 9:jiaf005. doi: 10.1093.
    PubMed     Abstract available
    
    
    
39. KOIRALA A, Smith K, Britton PN, Howard-Jones AR, et al
    Protracted Tuberculosis Outbreak in a Pasifika Diaspora in Western Sydney, Australia: The Importance of Community Engagement.
    J Infect Dis. 2025 Jan 9:jiae619. doi: 10.1093.
    PubMed     Abstract available
    
    
    
40. NOGUEIRA BMF, Rangel F, Andrade AMS, Daniel EA, et al
    Predictive Markers of Incident Tuberculosis in Close Contacts in Brazil and India.
    J Infect Dis. 2025 Jan 7:jiae642. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2024
41. DAY CL, Njuguna IN, Cranmer LM, Whatney WE, et al
    Patterns and cofactors of polyfunctional mycobacteria-specific T cell response restoration following 6-month antiretroviral treatment in children living with HIV.
    J Infect Dis. 2024 Dec 18:jiae630. doi: 10.1093.
    PubMed     Abstract available
    
    
    
42. MENDELSOHN SC, Andrade BB, Mbandi SK, Andrade AMS, et al
    Transcriptomic Signatures of Progression to Tuberculosis Disease Among Close Contacts in Brazil.
    J Infect Dis. 2024;230:e1355-e1365.
    PubMed     Abstract available
    
    
    
43. SEARS CL, Shah M
    The Evolution of Tuberculosis Community Transmission Science and its Ethical and Legal Constructs.
    J Infect Dis. 2024 Dec 11:jiae612. doi: 10.1093.
    PubMed    
    
    
    November 2024
44. ZHAI PY, Zang X, Jiang T, Feng J, et al
    Health and Economic Impacts of Introducing Vaccae and Enhanced Drug-Resistant Tuberculosis Management Strategies in China.
    J Infect Dis. 2024 Nov 22:jiae590. doi: 10.1093.
    PubMed     Abstract available
    
    
    
45. FERNANDES AI, Pinto AJ, Silverio D, Zedler U, et al
    Genetically diverse Mycobacterium tuberculosis isolates manipulate inflammasome activation and IL-1beta secretion independently of macrophage metabolic rewiring.
    J Infect Dis. 2024 Nov 21:jiae583. doi: 10.1093.
    PubMed     Abstract available
    
    
    
46. RUELAS CASTILLO J, Guerrini V, Quijada D, Karanika S, et al
    Pharmacological inhibition of macrophage triglyceride biosynthesis pathways does not improve Mycobacterium tuberculosis control in infected mice.
    J Infect Dis. 2024 Nov 19:jiae577. doi: 10.1093.
    PubMed     Abstract available
    
    
    
47. HUANG X, Wu J, Xu J, Wang H, et al
    Mycobacterium tuberculosis Antigen Rv1471 Induces Innate Immune Memory and Adaptive Immunity against Infection.
    J Infect Dis. 2024 Nov 14:jiae572. doi: 10.1093.
    PubMed     Abstract available
    
    
    October 2024
48. THOMPSON RR, Kim S, Pelissari DM, Harada LO, et al
    High mortality rates among individuals misdiagnosed with tuberculosis: a matched retrospective cohort study of individuals diagnosed with tuberculosis in Brazil.
    J Infect Dis. 2024 Oct 28:jiae531. doi: 10.1093.
    PubMed     Abstract available
    
    
    
49. BI J, Guo Q, Gong Y, Chen X, et al
    Troglitazone reduces intracellular Mycobacterium tuberculosis survival via macrophage autophagy through LKB1-AMPKalpha signaling.
    J Infect Dis. 2024 Oct 25:jiae523. doi: 10.1093.
    PubMed     Abstract available
    
    
    
50. RAJAGOPALAN S, Rourke AK, Asare E, Kohlerschmidt DJ, et al
    Engineered Mycobacteriophage TM4::GeNL Rapidly Determines Bedaquiline, Pretomanid, Linezolid, Rifampicin, and Clofazimine Sensitivity in Mycobacterium tuberculosis Clinical Isolates.
    J Infect Dis. 2024 Oct 16:jiae438. doi: 10.1093.
    PubMed     Abstract available
    
    
    
51. SCHALTZ-BUCHHOLZER F, Nielsen S, Sorensen MK, Gomes GM, et al
    Maternal Bacille Calmette-Guerin Scars and Mortality Risk for Male and Female Newborns: Observational Study From Guinea-Bissau.
    J Infect Dis. 2024;230:995-1003.
    PubMed     Abstract available
    
    
    
52. RIOPEL ND, Long R, Heffernan C, Tyrrell GJ, et al
    Characterization of Mycobacterium orygis, Mycobacterium bovis, and Mycobacterium caprae Infections in Humans in Western Canada.
    J Infect Dis. 2024;230:e789-e797.
    PubMed     Abstract available
    
    
    
53. NATHAVITHARANA RR, Pearl A, Biewer A, Tzelios C, et al
    Assessing infectiousness and the impact of effective treatment to guide isolation recommendations for people with pulmonary tuberculosis.
    J Infect Dis. 2024 Oct 7:jiae482. doi: 10.1093.
    PubMed     Abstract available
    
    
    
54. KARAKOUSIS PC, Mooney G
    Respiratory Isolation for Tuberculosis: A Historical Perspective.
    J Infect Dis. 2024 Oct 7:jiae477. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2024
55. WALKER NF, Schutz C, Ward A, Barr D, et al
    Elevated Plasma Matrix Metalloproteinases Are Associated With Mycobacterium tuberculosis Bloodstream Infection and Mortality in Human Immunodeficiency Virus-Associated Tuberculosis.
    J Infect Dis. 2024 Sep 2:jiae296. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2024
56. HORTON KC, McCaffrey T, Richards AS, Schwalb A, et al
    Estimating the impact of tuberculosis pathways on transmission - what is the gap left by passive case-finding?
    J Infect Dis. 2024 Aug 6:jiae390. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2024
57. CLARK RA, Sumner T, Weerasuriya CK, Bakker R, et al
    Estimating the Potential Public Health Value of BCG Revaccination.
    J Infect Dis. 2024;230:e139-e143.
    PubMed     Abstract available
    
    
    
58. GILS T, Hella J, Jacobs BKM, Sossen B, et al
    A prospective evaluation of the diagnostic accuracy of the point-of-care VISITECT CD4 Advanced Disease test in seven countries.
    J Infect Dis. 2024 Jul 24:jiae374. doi: 10.1093.
    PubMed     Abstract available
    
    
    
59. RAJAMANICKAM A, Ann Daniel E, Dasan B, Thiruvengadam K, et al
    Plasma Immune Biomarkers Predictive of Progression to Active Tuberculosis in Household Contacts of TB Patients.
    J Infect Dis. 2024 Jul 19:jiae365. doi: 10.1093.
    PubMed     Abstract available
    
    
    
60. KARLSSON L, Ohrnberg I, Sayyab S, Martinez-Enguita D, et al
    A DNA Methylation Signature from Buccal Swabs to Identify Tuberculosis Infection.
    J Infect Dis. 2024 Jul 4:jiae333. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2024
61. MUDDE SE, Ammerman NC, Ten Kate MT, Fotouhi N, et al
    Relative contributions of the novel diarylquinoline TBAJ-876 and its active metabolite to the bactericidal activity in a murine model of tuberculosis.
    J Infect Dis. 2024 Jun 28:jiae332. doi: 10.1093.
    PubMed     Abstract available
    
    
    
62. SINHA P, Guerrant RL
    The Costly Vicious Cycle of Infections and Malnutrition.
    J Infect Dis. 2024;229:1611-1613.
    PubMed     Abstract available
    
    
    May 2024
63. ARRIAGA MB, Amorim G, Figueiredo MC, Staats C, et al
    Effect of Smoking on Longitudinal Interferon-Upsilon Release Assay Results among Close Contacts of People with Pulmonary Tuberculosis.
    J Infect Dis. 2024 May 31:jiae285. doi: 10.1093.
    PubMed     Abstract available
    
    
    
64. DIXIT A, Ektefaie Y, Kagal A, Freschi L, et al
    Drug resistance and epidemiological success of modern Mycobacterium tuberculosis lineages in western India.
    J Infect Dis. 2024 May 31:jiae240. doi: 10.1093.
    PubMed     Abstract available
    
    
    
65. MEIWES L, Kontsevaya I, Chesov D, Kulcitkaia S, et al
    Whispers in the wind: Face mask sampling for Mycobacterium tuberculosis detection in children with pulmonary tuberculosis.
    J Infect Dis. 2024 May 27:jiae282. doi: 10.1093.
    PubMed     Abstract available
    
    
    
66. SPRINGER YP, Tompkins ML, Newell K, Jones M, et al
    Characterizing the etiology of recurrent tuberculosis using whole genome sequencing-Alaska, USA, 2008-2020.
    J Infect Dis. 2024 May 24:jiae275. doi: 10.1093.
    PubMed     Abstract available
    
    
    
67. ESPINOSA-PEREIRO J, Alagna R, Saluzzo F, Gonzalez-Moreno J, et al
    A Systematic Review of Potential Biomarkers for Bacterial Burden and Treatment Efficacy Assessment in Tuberculosis Platform-Based Clinical Trials.
    J Infect Dis. 2024;229:1584-1595.
    PubMed     Abstract available
    
    
    
68. TAGAMI Y, Horita N, Kaneko M, Muraoka S, et al
    Whole-Genome Sequencing Predicting Phenotypic Antitubercular Drug Resistance: Meta-analysis.
    J Infect Dis. 2024;229:1481-1492.
    PubMed     Abstract available
    
    
    
69. PETRILLO S, Di Prinzio RR, Quatrana A, Santoro A, et al
    Redox biomarkers in asymptomatic latent human tuberculosis: a comparison with active disease.
    J Infect Dis. 2024 May 9:jiae254. doi: 10.1093.
    PubMed     Abstract available
    
    
    
70. BALASINGAM S, Dheda K, Fortune S, Gordon SB, et al
    Review of the current TB human infection studies for use in accelerating TB vaccine development: A meeting report.
    J Infect Dis. 2024 May 6:jiae238. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2024
71. MORO RN, Mehaffy C, De P, Phillips E, et al
    Assessment for Antibodies to Rifapentine and Isoniazid in Persons Developing Flu-like Reactions During Treatment of Latent Tuberculosis Infection.
    J Infect Dis. 2024 Apr 19:jiae180. doi: 10.1093.
    PubMed     Abstract available
    
    
    
72. CROSS GB, O' Doherty J, Chang CC, Kelleher AD, et al
    Does PET-CT Have a Role in the Evaluation of Tuberculosis Treatment in Phase 2 Clinical Trials?
    J Infect Dis. 2024;229:1229-1238.
    PubMed     Abstract available
    
    
    
73. TAIT D, Diacon A, Borges AH, van Brakel E, et al
    Safety and immunogenicity of the H56:IC31 tuberculosis vaccine candidate in adults successfully treated for drug-susceptible pulmonary TB: a phase 1 randomized trial.
    J Infect Dis. 2024 Apr 1:jiae170. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2024
74. PATON NI, Gurumurthy M, Lu Q, Leek F, et al
    Adjunctive pascolizumab in rifampicin-susceptible pulmonary tuberculosis: proof-of-concept, partially-randomised, double-blind, placebo-controlled, dose-escalation trial.
    J Infect Dis. 2024 Mar 25:jiae104. doi: 10.1093.
    PubMed     Abstract available
    
    
    
75. OLSSON O, Sokilde R, Tesfaye F, Karlson S, et al
    Tuberculosis disease is associated with elevated plasma ribonuclease activity in antiretroviral treatment-naive people with HIV.
    J Infect Dis. 2024 Mar 25:jiae143. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2024
76. XIAO G, Huang W, Zhong Y, Ou M, et al
    Uncovering the Bronchoalveolar Single-Cell Landscape of Patients With Pulmonary Tuberculosis With Human Immunodeficiency Virus Type 1 Coinfection.
    J Infect Dis. 2024 Feb 27:jiae042. doi: 10.1093.
    PubMed     Abstract available
    
    
    
77. OH IS, Kim JH, Huh K, Jang SH, et al
    Impact of National Public-Private Mix and Medical Expense Support Program for Control Tuberculosis in South Korea: An Interrupted Time Series Analysis.
    J Infect Dis. 2024 Feb 14:jiae059. doi: 10.1093.
    PubMed     Abstract available
    
    
    
78. CHAUHAN KS, Dunlap MD, Akter S, Gupta A, et al
    NF-kappaB signaling deficiency in CD11c-expressing phagocytes mediates early inflammatory responses and enhances Mycobacterium tuberculosis control.
    J Infect Dis. 2024 Feb 7:jiae060. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2024
79. ZHENG Q, Li Z, Zhou Y, Li Y, et al
    Heparin-binding hemagglutinin of Mycobacterium tuberculosis inhibits autophagy via TLR4 and drives M2 polarization in macrophages.
    J Infect Dis. 2024 Jan 24:jiae030. doi: 10.1093.
    PubMed     Abstract available
    
    
    
80. PEI X, Zhong T, Yang C, Sun L, et al
    Cost-Effectiveness of Community-Based Active Case Finding Strategy for Tuberculosis: Evidence from Shenzhen, China.
    J Infect Dis. 2024 Jan 23:jiae024. doi: 10.1093.
    PubMed     Abstract available
    
    
    
81. RIDOLFI F, Amorim G, Peetluk LS, Haas DW, et al
    Prediction models for adverse drug reactions during tuberculosis treatment in Brazil.
    J Infect Dis. 2024 Jan 23:jiae025. doi: 10.1093.
    PubMed     Abstract available
    
    
    
82. HUYNH J, Le NHT, Nguyen BHL, Hoang HT, et al
    The ability of a 3-gene host signature in blood to distinguish tuberculous meningitis from other brain infections.
    J Infect Dis. 2024 Jan 3:jiad606. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2023
83. ZAINABADI K, Vilbrun SC, Mathurin LD, Walsh KF, et al
    A bedaquiline, pyrazinamide, levofloxacin, linezolid, clofazimine second line regimen for tuberculosis displays similar early bactericidal activity as the standard rifampin based first line regimen.
    J Infect Dis. 2023 Dec 7:jiad564. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2023
84. BLAZEVIC A, Edwards RL, Xia M, Eickhoff CS, et al
    Phase 1 Open-Label Dose Escalation Trial for the Development of a Human Bacillus Calmette-Guerin Challenge Model for Assessment of Tuberculosis Immunity In Vivo.
    J Infect Dis. 2023 Nov 29:jiad441. doi: 10.1093.
    PubMed     Abstract available
    
    
    
85. YUEN CM, Huang CC, Millones AK, Calderon RI, et al
    Utility of Mycobacterium tuberculosis genome sequencing snapshots to assess transmission dynamics over time.
    J Infect Dis. 2023 Nov 23:jiad515. doi: 10.1093.
    PubMed     Abstract available
    
    
    October 2023
86. SINGH B, Pahuja I, Yadav P, Shaji A, et al
    Adjunct therapy with all-trans-retinoic acid improves therapeutic efficacy through immunomodulation while treating tuberculosis with antibiotics in a murine model.
    J Infect Dis. 2023 Oct 21:jiad460. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2023
87. ESCUDERO JN, Mecha J, Richardson BA, Maleche-Obimbo E, et al
    Impact of HIV and peripartum period on Mycobacterium tuberculosis infection detection.
    J Infect Dis. 2023 Sep 28:jiad416. doi: 10.1093.
    PubMed     Abstract available
    
    
    
88. ABDELGAWAD N, Wasserman S, Abdelwahab MT, Davis A, et al
    Linezolid population pharmacokinetic model in plasma and cerebrospinal fluid among patients with tuberculosis meningitis.
    J Infect Dis. 2023 Sep 22:jiad413. doi: 10.1093.
    PubMed     Abstract available
    
    
    
89. NORE KG, Louet C, Bugge M, Gidon A, et al
    The Cyclooxygenase 2 inhibitor etoricoxib as adjunctive therapy in tuberculosis impairs macrophage control of mycobacterial growth.
    J Infect Dis. 2023 Sep 18:jiad390. doi: 10.1093.
    PubMed     Abstract available
    
    
    
90. RASI V, Phelps KR, Paulson KR, Eickhoff CS, et al
    Homodimeric Granzyme A opsonizes Mycobacterium tuberculosis and inhibits its intracellular growth in human monocytes via TLR4 and CD14.
    J Infect Dis. 2023 Sep 6:jiad378. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2023
91. HILL PC, Cobelens F, Martinez L, Behr MA, et al
    An aspiration to radically shorten phase 3 TB vaccine trials.
    J Infect Dis. 2023 Aug 22:jiad356. doi: 10.1093.
    PubMed     Abstract available
    
    
    
92. MCSHANE H
    Improving TB vaccine trial efficiency: A tough nut to crack.
    J Infect Dis. 2023 Aug 21:jiad360. doi: 10.1093.
    PubMed    
    
    
    June 2023
93. MAENETJE P, Baik Y, Schramm DB, Vangu MDW, et al
    Circulating biomarkers, FeNO, and lung function in patients with HIV and tuberculosis.
    J Infect Dis. 2023 Jun 30:jiad232. doi: 10.1093.
    PubMed     Abstract available
    
    
    
94. SINGH DK, Bhaskar A, Pahuja I, Shaji A, et al
    Co-treatment with Clofazimine and Rapamycin eliminates drug-resistant tuberculosis by inducing polyfunctional central memory T cell responses.
    J Infect Dis. 2023 Jun 8:jiad214. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2023
95. CHEN S, Li C, Qin Z, Song L, et al
    Serum metabolomic profiles for distinguishing lung cancer from pulmonary tuberculosis: identification of rapid and noninvasive biomarker.
    J Infect Dis. 2023 May 29:jiad175. doi: 10.1093.
    PubMed     Abstract available
    
    
    
96. RAMALINGAM S, Kumar A, Krug S, Mohan H, et al
    CRISPR correction of GBA mutation in hiPSCs restores normal function to Gaucher macrophages and increases their susceptibility to Mycobacterium tuberculosis.
    J Infect Dis. 2023 May 9:jiad141. doi: 10.1093.
    PubMed     Abstract available
    
    
    
97. BORBORA SM, Satish BA, Sundar S, B M, et al
    Mycobacterium tuberculosis elevates SLIT2 expression within the host and contributes to oxidative stress responses during infection.
    J Infect Dis. 2023 May 9:jiad126. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2023
98. VAN DER HEIJDEN YF, Maruri F, Blackman A, Morrison R, et al
    Mycobacterium tuberculosis gene expression associated with fluoroquinolone resistance and efflux pump inhibition.
    J Infect Dis. 2023 Apr 20:jiad112. doi: 10.1093.
    PubMed     Abstract available
    
    
    
99. ALEMNJI G, Mosha F, Maggiore P, Alexander H, et al
    Building Integrated Testing Programs for Infectious Diseases.
    J Infect Dis. 2023 Apr 12:jiad103. doi: 10.1093.
    PubMed     Abstract available
    
    
    
100. ROCCO JM, Laidlaw E, Galindo F, Anderson M, et al
     Mycobacterial Immune Reconstitution Inflammatory Syndrome in HIV is Associated With Protein-Altering Variants in Hemophagocytic Lymphohistiocytosis-Related Genes.
     J Infect Dis. 2023 Apr 11:jiad059. doi: 10.1093.
     PubMed     Abstract available
     
     
     February 2023
101. SABO MC, Thuong NTT, Chang X, Ardiansyah E, et al
     MUC5AC genetic variation is associated with tuberculous meningitis CSF cytokine responses and mortality.
     J Infect Dis. 2023 Feb 24:jiad050. doi: 10.1093.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Tuberculosis is free of charge.